Summary
Cabaletta Bio (CABA) is pioneering the use of CAAR-T cell therapies to potentially cure various autoimmune diseases. The company was founded in 2017 to use clinically-validated CAR-T technologies to target B-cell mediated autoimmune disease. A primary feature of autoimmune disease is the loss of B-cell tolerance and the production of autoantibodies (i.e. they attack self). There are more than 80 autoimmune diseases from rheumatoid arthritis ((RA)) to multiple sclerosis ((MS)) to systemic lupus erythematosus (SLE). CAR-T is a technology to engineer T-cells to specifically kill cancer cells. CAR-T has several FDA